TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06570915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
Study: NCT04228991

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional radiation treatment - Conventional fractionation
Description: 40 Gray in 15 daily fractions over 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Locoregional radiation treatment - Hypofractionation
Description: 26 Gray in 5 daily fractions over 1 week
Study: NCT06523426

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient treated by spinal endoscopy
Description: Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
Study: NCT05520619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
Study: NCT05741034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLITE™
Description: Injection, subdermal and/or intradermal

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No-treatment control
Study: NCT05175352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP substrates
Description: Specified dose on specified days
Study: NCT06357416

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MV-PRS Sub-study
Description: Patients consenting to polygenic risk score testing

Intervention type: OTHER
Group type: OTHER
Intervention: MV-DNA and MV-UctDNA Sub-study
Description: Patients consenting to collection of DNA and urine for further study.

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: Man Van patients
Description: All patients seen in Man Van

Intervention type: OTHER
Group type: OTHER
Intervention: MV-SSI Sub-study
Description: Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.

Intervention type: OTHER
Group type: OTHER
Intervention: MV-TPP Sub-study
Description: Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
Study: NCT05921812

Intervention type: DIAGNOSTIC_TEST
Intervention: real time pcr
Description: evaluate the expression of certain circulating microRNAs by real time pcr

Intervention type: DIAGNOSTIC_TEST
Intervention: real time pcr
Description: evaluate the expression of certain circulating microRNAs by real time pcr
Study: NCT06127771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programming DBS using Percept PC neurostimulator's full potential
Description: This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
Study: NCT04236947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCPP-YA
Description: SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
Study: NCT06286657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT05391828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design
Description: TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design
Description: TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT06605677

Intervention type: OTHER
Intervention: Questionnaire
Description: An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
Study: NCT06543381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given PO
Study: NCT04875533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study: NCT06394661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serulizumab 4.5mg/Kg ivgtt on Day 3）every 3 weeks for 6 cycles. NabPE+Sluritumab group（Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serulizumab 4.5mg/Kg ivgtt on Day 3）every 3 weeks for 6 cycles. Serulizumab will be given as monotherapy every 3 weeks up to 6 months from the begining of the treatment after surgery.
Study: NCT05298384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression stockings
Description: Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
Study: NCT05324982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBG Cannabis
Description: CBG cannabis oil will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBG Cannabis
Description: CBG cannabis oil will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBG Cannabis
Description: CBG cannabis oil will be orally self-administered by study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBG Cannabis
Description: CBG cannabis oil will be orally self-administered by study participants.
Study: NCT06426771

Intervention type: BEHAVIORAL
Intervention: Dietary Inflammatory Index
Description: The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.

Intervention type: BEHAVIORAL
Intervention: Dietary Inflammatory Index
Description: The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
Study: NCT06426771

Intervention type: BEHAVIORAL
Intervention: Dietary Inflammatory Index
Description: The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.

Intervention type: DIAGNOSTIC_TEST
Intervention: hormone profile
Description: In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.

Intervention type: DIAGNOSTIC_TEST
Intervention: hormone profile
Description: In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.

Intervention type: DIAGNOSTIC_TEST
Intervention: hormone profile
Description: In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
Study: NCT06615596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discontinue anticoagulation therapy
Description: Participants in the discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant drugs
Description: Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT06615596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
Study: NCT04715178

Intervention type: OTHER
Intervention: No intervention- registry only
Description: No intervention- registry only
Study: NCT05761925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMA-F
Description: The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.
Study: NCT06668480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening Exercise
Description: Strengthening exercises of lower fibers of trapezius

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNAG'S
Description: Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNAG'S
Description: Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks
Study: NCT06615687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted T shape Free Gingival Graft
Description: the preparation of the recipient site commenced by making a horizontal incision at the mucogingival junction (MGJ) as well as two vertical incisions extending to the adjacent teeth and about 3-4 mm beyond the MGJ. A sharp split-thickness flap will be reflected, and the surfaces between these incisions will be de-epithelialized. Also, all the surfaces of the interdental papilla up to the lingual side will be de-epithelized using a 15c blade and microsurgical scissor .(Harvesting of the palatal donor site will be designed 2 mm away from the gingival margin using a template in the form of an inverted T-shape, taking into consideration the position of the greater palatine blood vessels at 5 mm. 2 mm is required for the width of the interproximal extension with 3 mm length to obtain an even thickness of 1-1.5 mm .~Placement of the graft : The Inverted T FGG will be inserted between the teeth to cover interproximal tissue defect and sutured lingually into the lingual marginal gingiva

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Preparation of the recipient site :Following an intrasulcular incision, 2 mm-long horizontal incisions at the level of the CEJ will be performed bilaterally. From these, vertical releasing incisions will be placed in a diverging manner, extending well into the alveolar mucosa, a thin partial thickness flap will be subsequently raised then excised. The dimension of the resulting site will be measured to obtain a rectangular foil template .~Harvesting of the Graft :Using the foil template, graft dimensions will be outlined in the palate adjacent to the premolars and first molar. A partial thickness graft consisting of epithelium and a thin layer of underlying connective tissue will be harvested (intended total thickness of graft: 1.5 mm), maintaining a distance of ≥2 mm to the maxillary teeth.
Study: NCT06617962

Intervention type: DIAGNOSTIC_TEST
Intervention: CBA method of live cells and fixed cells
Description: 1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: CBA method of live cells and fixed cells
Description: 1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples.
Study: NCT06613490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti CD19 CAR NK cells
Description: This study is a single-arm, open-label and single-center exploratory clinical study to evaluate the safety and effectiveness of anti CD19 CAR NK cells in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA). All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by Anti-CD19 CAR NK cells infusion.